Acurx pharmaceuticals announces presentation of results from leiden university medical center public-private partnership for its dna pol iiic inhibitors at the federation of american societies for experimental biology scientific conference

Results are from acurx's ongoing scientific collaboration with leiden university medical center (lumc) partially under a grant from health holland to further study the mechanism of action of  dna pol iiic inhibitors lumc highlighted acurx's new class of promising antimicrobials, ibezapolstat and related analogues novel chemotype specifically targeting gram-positive bacteria through an unexploited target ibezapolstat ready to enter pivotal phase 3 clinical trials for c. difficile infection (cdi), with no cross resistance reported to date ibezapolstat has previously been granted fda qidp and fast-track designations and has received sme (small and medium-sized enterprise) designation by the ema staten island, n.y.
DNA Ratings Summary
DNA Quant Ranking